A pilot randomized, controlled trial of later treatment with a peptide-containing, synthetic surfactant for the prevention of bronchopulmonary dysplasia (Pediatrics (2009) 123, 1, (89-96) DOI: 10.1542/peds.2007-2680);A pilot randomized, controlled trial of later treatment with a peptide-containing, synthetic surfactant for the prevention of bronchopulmonary dysplasia

Pediatrics

Volumn 123, Issue 1, 2009, Pages 89-96

  Laughon, Matthew ^a,h   Bose, Carl ^a   Moya, Fernando ^b   Aschner, Judy ^c   Donn, Steven Mark ^d   Morabito, Christopher ^e   Cummings, James John ^f   Segal, Robert ^g   Guardia, Carlos ^g   Liu, Genzhou ^g  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NEW HANOVER REGIONAL MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e LEHIGH VALLEY HOSPITAL   (United States)

^f EAST CAROLINA UNIVERSITY   (United States)

^g Discovery Laboratories   (United States)

^h UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

Author keywords

Bronchopulmonary dysplasia; Premature infant; Surfactant

Indexed keywords

LUCINACTANT; PLACEBO; FATTY ALCOHOL; LUNG SURFACTANT; PEPTIDE; PHOSPHATIDYLGLYCEROL; PROTEIN;

ARTICLE; ARTIFICIAL VENTILATION; BRADYCARDIA; BRAIN HEMORRHAGE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ENCEPHALOMALACIA; FEMALE; HIGH RISK PATIENT; HUMAN; LUNG DYSPLASIA; LUNG EMPHYSEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NECROTIZING ENTEROCOLITIS; NEWBORN; NEWBORN MORTALITY; OPTIMAL DRUG DOSE; OXYGEN CONSUMPTION; OXYGEN SATURATION; OXYGEN THERAPY; PATENT DUCTUS ARTERIOSUS; PILOT STUDY; PNEUMOTHORAX; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROLENTAL FIBROPLASIA; SIDE EFFECT; SINGLE BLIND PROCEDURE; CHEMISTRY; COMPARATIVE STUDY; DRUG COMBINATION; INTERNATIONAL COOPERATION; MORTALITY;

BRONCHOPULMONARY DYSPLASIA; DRUG COMBINATIONS; FATTY ALCOHOLS; FEMALE; HUMANS; INFANT, NEWBORN; INTERNATIONALITY; MALE; PEPTIDES; PHOSPHATIDYLGLYCEROLS; PILOT PROJECTS; PROTEINS; PULMONARY SURFACTANTS;

EID: 59449110420     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2009-0533     Document Type: Erratum

References (26)

1. Wilson-Costello D, Friedman H, Minich N, et al. Improved neurodevelopmental outcomes for extremely low birth weight infants in 2000-2002. Pediatrics. 2007;119(1):37-45
2. Hoekstra RE, Ferrara TB, Couser RJ, Payne NR, Connett JE. Survival and long-term neurodevelopmental outcome of extremely premature infants born at 23-26 weeks' gestational age at a tertiary center. Pediatrics. 2004;113(1). Available at: www.pediatrics.org/cgi/content/full/113/1/e1
3. Kinsella JP, Greenough A, Abman SH. Bronchopulmonary dysplasia. Lancet. 2006;367(9520):1421-1431
4. Soll RF. Synthetic surfactant for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev. 2000(2):CD001149
5. Soll RF. Prophylactic synthetic surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2000(2):CD001079
6. Soll RF. Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2000(2):CD000511
7. Chida S, Fujiwara T, Konishi M, Shimada S, Takahashi A. Surfactant proteins and stable microbubbles in tracheal aspirates of infants with respiratory distress syndrome: relation to the degree of respiratory failure and response to exogenous surfactant. Eur J Pediatr. 1997;156(2):131-138
8. Ballard PL, Merrill JD, Godinez RI, Godinez MH, Truog WE, Ballard RA. Surfactant protein profile of pulmonary surfactant in premature infants. Am J Respir Crit Care Med. 2003;168(9): 1123-1128
9. Merrill JD, Ballard RA, Cnaan A, et al. Dysfunction of pulmonary surfactant in chronically ventilated premature infants. PediatrRes. 2004;56(6):918-926
10. Pandit PB, Dunn MS, Kelly EN, Perlman M. Surfactant replacement in neonates with early chronic lung disease. Pediatrics.1995;95(6):851-854
11. Bissinger R, Carlson C, Hulsey T, Eicher D. Secondary surfactant deficiency in neonates. J Perinatol. 2004;24(10):663-666
12. Katz LA, Klein JM. Repeat surfactant therapy for postsurfac- tant slump. J Perinatol. 2006;26(7):414-422
13. Charafeddine L, D'Angio CT, Phelps DL. Atypical chronic lung disease patterns in neonates. Pediatrics. 1999;103(4 pt 1):759-765
14. Andersson S, Kheiter A, Merritt TA. Oxidative inactivation of surfactants. Lung. 1999;177(3):179-189
15. Amirkhanian JD, Merritt TA. Inhibitory effects of oxyradicals on surfactant function: utilizing in vitro Fenton reaction. Lung. 1998;176(1):63-72
16. Manalo E, Merritt TA, Amirkhanian JD, Kheiter A. Characterization of surfactant subtypes of beractant and a synthetic peptide containing surfactant KL4 following surface area cycling and addition of fibrinogen. Lung. 1997;175(4):225-233
17. Kinniry P, Pick J, Stephens S, et al. KL4-surfactant prevents hyperoxic and LPS-induced lung injury in mice. Pediatr Pulmo- nol. 2006;41(10):916-928
18. Moya FR, Gadzinowski J, Bancalari E, et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfos- ceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics. 2005; 115(4):1018-1029
19. Sinha SK, Lacaze-Masmonteil T, Valls i Soler A, et al. A multi- center, randomized, controlled trial of lucinactant versus porac- tant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics. 2005;115(4):1030-1038
20. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr. 1978;92(4):529-534
21. Donn SM. Lucinactant: a novel synthetic surfactant for the treatment of respiratory distress syndrome. Expert Opin Investig Drugs. 2005;14(3):329-334
22. Ballard RA, Truog WE, Cnaan A, et al. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med. 2006;355(4):343-353
23. Tyson JE, Wright LL, Oh W, et al. Vitamin A supplementation for extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med. 1999;340(25):1962-1968
24. Liechty EA, Donovan E, Purohit D, et al. Reduction of neonatal mortality after multiple doses of bovine surfactant in low birth weight neonates with respiratory distress syndrome. Pediatrics.1991;88(1):19-28
25. Hudak ML, Farrell EE, Rosenberg AA, et al. A multicenter randomized, masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome. J Pediatr. 1996;128(3):396 -406
26. Walsh MC, Wilson-Costello D, Zadell A, Newman N, Fan- aroff A. Safety, reliability, and validity of a physiologic definition of bronchopulmonary dysplasia. J Perinatol. 2003; 23(6):451-456